You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CPD

Generalized Pustular Psoriasis: What Do You Know?

  • Authors: Jonathan Barker, MD; Melinda Gooderham, MD; Ulrich Mrowietz, MD; Luis Puig, MD, PhD
  • CPD Released: 7/23/2020
  • THIS ACTIVITY HAS EXPIRED
  • Valid for credit through: 7/23/2021
Start Activity


Target Audience and Goal Statement

This educational activity is intended for an international audience of non-US dermatologists and primary care physicians.

The goal of this activity is to provide foundational education about generalized pustular psoriasis (GPP), the causes of the disease, clinical signs and symptoms and the impact of associated complications that can occur in patients with this skin disease.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Causes of GPP
    • Clinical characteristics of GPP
    • Complications associated with GPP


Disclosures

WebMD Global requires each individual who is in a position to control the content of one of its educational activities to disclose any relevant financial relationships occurring within the past 12 months that could create a conflict of interest.


Faculty

  • Jonathan Barker, MD

    Professor of Medical Dermatology and Consultant Dermatologist
    St. John's Institute of Dermatology
    Guy's and St Thomas's Hospitals
    London, UK

    Disclosures

    Disclosure: Jonathan Barker, MD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: AbbVie Inc.; Almirall Hermal GmbH; Amgen Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Celgene Corporation; Eli Lilly and Company; Janssen Pharmaceuticals; LEO Pharma; Novartis Pharmaceuticals Corporation; Samsung; Sun Pharma
    Served as a speaker or a member of a speakers bureau for: AbbVie Inc.; Almirall Hermal GmbH; Amgen Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Celgene Corporation; Eli Lilly and Company; Janssen Pharmaceuticals; LEO Pharma; Novartis Pharmaceuticals Corporation; Samsung; Sun Pharma
    Received grants for clinical research from: AbbVie Inc.; Almirall Hermal GmbH; Amgen Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Celgene Corporation; Eli Lilly and Company; Janssen Pharmaceuticals; LEO Pharma; Novartis Pharmaceuticals Corporation; Samsung; Sun Pharma

  • Melinda Gooderham, MD

    Medical Director at SKiN Centre for Dermatology
    Investigator with Probity Medical Research
    Assistant Professor at Queens University
    Consultant Physician at the Peterborough Regional Health Centre
    Peterborough, Ontario, Canada

    Disclosures

    Disclosure: Melinda Gooderham, MD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: AbbVie Inc.; Actelion Pharmaceuticals, Ltd; Akros; Amgen Inc.; Bausch & Lomb Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Celgene Corporation; Eli Lilly and Company; Galderma Laboratories, L.P.; Glenmark; Janssen Pharmaceuticals; Kyowa; LEO Pharma; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Regeneron Pharmaceuticals, Inc.; Sanofi; Sun Pharmaceuticals; UCB Pharma, Inc.
    Served as a speaker or a member of a speakers bureau for: AbbVie Inc.; Actelion Pharmaceuticals, Ltd; Akros; Amgen Inc.; Bausch & Lomb Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Celgene Corporation; Eli Lilly and Company; Galderma Laboratories, L.P.; Glenmark; Janssen Pharmaceuticals; Merck & Co., Inc; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Regeneron Pharmaceuticals, Inc.; Sanofi; Sun Pharmaceuticals; UCB Pharma, Inc.
    Other: AbbVie Inc.; Akros; Amgen Inc.; Bausch & Lomb Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; Celgene Corporation; Coherus; Dermira Inc.; Eli Lilly and Company; Galderma Laboratories, L.P.; Glenmark; Janssen Pharmaceuticals; Kyowa; LEO Pharma; MedImmune Inc.; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Regeneron Pharmaceuticals, Inc.; Roche Holdings AG; Sanofi; Sun Pharmaceuticals; UCB Pharma, Inc.

  • Ulrich Mrowietz, MD

    Head of Psoriasis-Center
    Dept. of Dermatology, Venerology and Allergology
    University Medical Center Schleswig-Holstein
    Kiel, Germany

    Disclosures

    Disclosure: Ulrich Mrowietz, MD, has disclosed the following financial relationships:
    Served as an advisor or consultant for: AbbVie; Almirall; Aristea, Boehringer-Ingelheim; Celgene, Dr. Reddy’s; Eli Lilly; Foamix, Formycon; Forward Pharma; Janssen; LEO Pharma, Medac, Novartis; Pierre
    Fabre; Sanofi-Aventis; UCB; Xenoport
    Served as a speaker or a member of a speakers bureau for: AbbVie; Almirall; Boehringer-Ingelheim; Celgene; Eli Lilly; Janssen; LEO Pharma; Medac; Novartis; UCB
    Received grants for clinical research from: AbbVie; Almirall, Celgene; Forward Pharma; Novartis; UCB
     

  • Luis Puig, MD, PhD

    Director
    Hospital de la Santa CreuI Sant Pau
    Universitat Autònomade Barcelona
    Barcelona, Spain

    Disclosures

    Disclosure: Luis Puig, MD, PhD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: AbbVie Inc.; Almirall Hermal GmbH; Amgen Inc.; Baxalta; Biogen; Boehringer Ingelheim Pharmaceuticals, Inc.; Celgene Corporation; Eli Lilly and Company; Freseius-Kabi; Janssen Pharmaceuticals; JS BIOCAD; LEO Pharma; Mylan Laboratories Inc.; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Regeneron Pharmaceuticals, Inc.; Roche Holdings AG; Sandoz; Samsung-Bioepis; Sanofi; UCB Pharma, Inc.
    Served as a speaker or a member of a speakers bureau for: AbbVie Inc.;Almirall Hermal GmbH; Amgen Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Celgene Corporation; Eli Lilly and Company; Janssen Pharmaceuticals; LEO Pharma; Mylan Laboratories Inc.; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Regeneron Pharmaceuticals, Inc.; Roche Holdings AG; Sandoz; Samsung-Bioepis; Sanofi; UCB Pharma, Inc.
    Received grants for clinical research from: Celgene Corporation; Eli Lilly and Company; Janssen Pharmaceuticals; Novartis Pharmaceuticals Corporation; Pfizer
    Owns stock, stock options, or bonds from: AbbVie Inc.; Almirall Hermal GmbH; Amgen Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Celgene Corporation; Eli Lilly and Company; Janssen Pharmaceuticals; LEO Pharma; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Regeneron Pharmaceuticals, Inc.; Roche Holdings AG; Sanofi; UCB Pharma, Inc.

Editor

  • Marinella Calle, PhD, CMPP

    Medical Education Director, WebMD Global, LLC

    Disclosures

    Disclosure: Marinella Calle, PhD, CMPP, has disclosed no relevant financial relationships.

Content Reviewer

  • Robert Morris, PharmD

    Associate Director, Accreditation and Compliance

    Disclosures

    Disclosure: Robert Morris, PharmD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: ViiV Healthcare
    Owns stock, stock options, or bonds from: GlaxoSmithKline

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.


Accreditation Statements

    For Physicians

  • The Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom (FPM) has reviewed and approved the content of this educational activity and allocated it 0.50 continuing professional development credits (CPD).

    Contact WebMD Global

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information about your eligibility to claim credit, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent participating in the activity. To successfully earn credit, participants must complete the activity online during the credit eligibility period that is noted on the title page.

Follow these steps to claim a credit certificate for completing this activity:

  1. Read the information provided on the title page regarding the target audience, learning objectives, and author disclosures, read and study the activity content and then complete the post-test questions. If you earn a passing score on the post-test and we have determined based on your registration profile that you may be eligible to claim CPD credit for completing this activity, we will issue you a CPD credit certificate.
  2. Once your CPD credit certificate has been issued, you may view and print the certificate from your CME/CE Tracker. CPD credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of the Medscape Education homepage.

We encourage you to complete an Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of your Medscape homepage.

*The credit that you receive is based on your user profile.

CPD

Generalized Pustular Psoriasis: What Do You Know?

Authors: Jonathan Barker, MD; Melinda Gooderham, MD; Ulrich Mrowietz, MD; Luis Puig, MD, PhDFaculty and Disclosures
THIS ACTIVITY HAS EXPIRED

CPD Released: 7/23/2020

Valid for credit through: 7/23/2021

processing....

Contents of This CPD Activity

All sections of this activity are required for credit.

Generalized Pustular Psoriasis: What Do You Know?

Dr Barker covers the prevalence and causes of GPP.
Jonathan Barker, MD

Signs and Symptoms of Generalized Pustular Psoriasis

Dr Mrowietz presents the signs and symptoms of GPP.
Ulrich Mrowietz, MD

Impact of Generalized Pustular Psoriasis on Patients' Lives

Dr Puig covers the impact of this skin disease on patients.
Luis Puig, MD, PhD

Therapeutic Management of Generalized Pustular Psoriasis

Dr Gooderham presents the current options for treatment of GPP.
Melinda Gooderham, MD

Concluding Remarks

Dr Barker outlines the conclusions of the activity.
Jonathan Barker, MD

Educational Impact Challenge

The goal of this activity is to provide foundational education about generalized pustular psoriasis (GPP), the causes of the disease, clinical signs and symptoms and the impact of associated complications that can occur in patients with this skin disease.

Before you begin this activity, please assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.